FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 115 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR A New FDA Approval Furthers the Role of Genomics in Cancer... July 8, 2020 Easing Concerns about Giving Research Study Participants Their Genetic Test Results June 1, 2018 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 What to Know About Cancer Clinical Trial Matching Programs March 14, 2023 Load more HOT NEWS Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... COVID-19 May Have Saved a Woman’s Life by Helping Her Discover... EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of...
